Chemotherapy-Free Management of Indolent Lymphoma


In this video by VJHemOnc – Video Journal of Hematological Oncology, Wolfgang Hiddemann, MD, PhD, provides an overview of chemotherapy-free approaches in clinical development for the treatment of patients with indolent lymphoma.

Promising approaches include the Bruton tyrosine kinase inhibitor, ibrutinib, and PI3K-delta inhibitor, idelalisib, in combinations with anti-CD20 monoclonal antibodies; Bcl-2 inhibitors; and PD-1 immune checkpoint inhibitors.

Learn more about lymphoma here:

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published.